X

Trial Profile

Phase II Clinical Study of CM082 Combined With JS001 in the Treatment of Advanced Mucinous Melanoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary) ; Vorolanib (Primary)
Indications Malignant melanoma
Focus Therapeutic Use
Sponsors AnewPharma

Most Recent Events

31 May 2020 Results (data cut-off November 28, 2019; n= 29), investigatinf the safety and efficacy of CM082 in combination with JS001 in patients (pts) with advanced mucosal melanoma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
02 Jul 2019 Planned number of patients changed from 20 to 40.
19 Feb 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com